Pyridazinone compounds and methods for the treatment of cystic fibrosis

A compound having the formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• m is 2 to 5;
• each R2 is independently selected from hydrogen, deuterium, halogen, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl —OR100, —SR100, —NR100R101, —C(O)R100, —C(O)OR100, —C(O)NR100R101, —N(R100)C(O)R101, —S(O)2R100, —S(O)R100, —SR100, —S(O)2N(R100)R101, —CF3, —CN, —NO2, and —N3;
• provided that two R2 groups, together with the atoms to which they are attached, form an optionally substituted 3, 4, 5, 6 or 7 membered ring;
• A1 is —[C(R100)(R101)]n-, —C(O)—, —C(S)—, —S(O)—, —C(O)N(R100)—, —S(O)2N(R100)—, —S(O)2—, carbocycle, substituted carbocycle, heterocycle, substituted heterocycle, aromatic, substituted aromatic, heteroaromatic or substituted heteroaromatic;
• n is 0, 1, 2, 3, 4, 5, 6 or 7;
• each R100 and R101 is independently hydrogen, deuterium, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aliphatic, substituted aliphatic, aryl and substituted aryl;
• alternatively two R100 groups or an R100 group and an R101 group, together with the atoms to which they are attached and any intervening atoms, form an additional optionally substituted, 3, 4, 5, 6 or 7 membered ring;
• A2 is —[C(R100)(R101)]n—, —C(O)—, —C(S)—, —S(O)—, —C(O)N(R′100)—, and —S(O)2;
• R′100 is alkyl;
• A3 is absent;
• Cy2 is an aryl or substituted aryl;
• Cy1 is an aryl, substituted aryl, carbocycle, substituted carbocycle, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl group having one, two or three rings.